Pirker R, Keilhauer G, Raschack M, Lechner C, Ludwig H
First Medical Clinic, Vienna, Austria.
Int J Cancer. 1990 May 15;45(5):916-9. doi: 10.1002/ijc.2910450523.
Several structural analogs of verapamil were studied for their ability to reverse multi-drug resistance (MDR) in human KB cell lines. D595, D792 and verapamil completely reversed resistance to colchicine and adriamycin. D595 and D792 had a higher reversing potency than verapamil. Devapamil, gallopamil, emopamil and D528 partially reversed MDR. The reversing potency of a drug did not correlate with its calcium antagonistic activity. No differences in reversing potency between (R)-isomers, (L)-isomers and the racemic forms were observed in the case of both verapamil and emopamil. (R)-verapamil, which has less calcium antagonistic activity and less in vivo toxicity than racemic verapamil, and D792, which has higher reversing potency and less in vivo toxicity than racemic verapamil, should be suitable for clinical applications to overcome drug resistance in cancer patients.
研究了维拉帕米的几种结构类似物在人KB细胞系中逆转多药耐药(MDR)的能力。D595、D792和维拉帕米完全逆转了对秋水仙碱和阿霉素的耐药性。D595和D792的逆转效力高于维拉帕米。地伐帕米、加洛帕米、依莫帕米和D528部分逆转了MDR。一种药物的逆转效力与其钙拮抗活性无关。在维拉帕米和依莫帕米的情况下,未观察到(R)-异构体、(L)-异构体和外消旋体在逆转效力上的差异。与外消旋维拉帕米相比,钙拮抗活性较低且体内毒性较小的(R)-维拉帕米,以及与外消旋维拉帕米相比,逆转效力较高且体内毒性较小的D792,应适合临床应用以克服癌症患者的耐药性。